0.79
-0.0058(-0.73%)
Currency In USD
| Previous Close | 0.8 |
| Open | 0.76 |
| Day High | 0.8 |
| Day Low | 0.74 |
| 52-Week High | 7.5 |
| 52-Week Low | 0.65 |
| Volume | 119,714 |
| Average Volume | 149,574 |
| Market Cap | 5.88M |
| PE | -0.11 |
| EPS | -7.13 |
| Moving Average 50 Days | 0.73 |
| Moving Average 200 Days | 1.49 |
| Change | -0.01 |
If you invested $1000 in Pasithea Therapeutics Corp. (KTTA) since IPO date, it would be worth $11.1 as of September 08, 2025 at a share price of $0.79. Whereas If you bought $1000 worth of Pasithea Therapeutics Corp. (KTTA) shares 3 years ago, it would be worth $30.39 as of September 08, 2025 at a share price of $0.79.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 29, 2025 12:39 PM GMT
MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced change of dat
Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Aug 28, 2025 11:02 AM GMT
MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced management wi
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
GlobeNewswire Inc.
Jul 31, 2025 11:01 AM GMT
– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 –MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology